Budget Impact Analysis Of Subcutaneous Belimumab In Patients With Systemic Lupus Erythematosus In Spain

References

• Working group of the Clinical Practice Guideline on Systemic Lupus Erythematosus. Clinical practice guideline on systemic lupus erythematosus. Clinical Practice Guidelines in the Spanish NHS. Ministry of Health, Social Services and Equality Evaluation Service of the Canary Islands Health Service; 2015
   Google Scholar
• Pons-Estel GJ, Ugarte-Gil MF, Alarcón GS. Epidemiology of systemic lupus erythematosus. Expert Rev Clin Immunol. 2017;13(8):799–814. doi:10.1080/1744666X2017.132735228471259
   PubMed Web of Science ®Google Scholar
• Trujillo-Martín MM, Rúa-figueroa Fernández de Larrinoa I, Ruíz-Irastorza G, et al. Clinical practice guidelines for systemic lupus erythematosus: recommendations for general clinical management. Med Clin (Barc). 2016;146(9):413.e1–413.e14. doi:10.1016/j.medcli.2016.01.013
   PubMedGoogle Scholar
• Chaigne B, Chizzolini C, Perneger T, et al. Impact of disease activity on health-related quality of life in systemic lupus erythematosus – a cross-sectional analysis of the Swiss Systemic Lupus Erythematosus Cohort Study (SSCS). BMC Immunol. 2017;18:17. doi:10.1186/s12865-017-0200-528351341
   PubMedGoogle Scholar
• Albrecht K, Huscher D, Richter J, et al. Changes in referral, treatment and outcomes in patients with systemic lupus erythematosus in Germany in the 1990s and the 2000s. Lupus Sci Med. 2014;1(1):e000059. doi:10.1136/lupus-2014-00005925553251
   PubMedGoogle Scholar
• Rodríguez Almaraz ME, Cámara Fernández I, Pablos Álvarez JL. Disseminated Lupus Erythematosus evaluation of the disease. Treatment management of complications. Med - Continued Accredited Medical Form Program. 2017;12(25):1440–1447. doi:10.1016/j.med.2017.01.002
   Google Scholar
• Calvo-Alén J, Silva-Fernández L, Úcar-angle E, et al. Consensus of the Spanish Society of Rheumatology on the use of biological therapies in systemic lupus erythematosus. Reumatol Clin. 2013;9(5):281–296.23871156
   PubMedGoogle Scholar
• Ramos-Casals M, Ruiz-Irastorza G, Jimenez-Alonso J, Khamashta MA. Recommendations on the use of belimumab in systemic lupus erythematosus. Clinical Practice Guide GEAS-SEMI. Rev Clin Esp. 2013;213(1):42–58. doi:10.1016/j.rce.2012.10.00423266125
   PubMedGoogle Scholar
• Doria A, Amoura Z, Cervera R, et al. Annual direct medical cost of active systemic lupus erythematosus in five European countries. Ann Rheum Dis. 2014;73(1):154–160. doi:10.1136/annrheumdis-2012-20244323264339
   PubMed Web of Science ®Google Scholar
• Cervera R, Rúa-Figueroa I, Gil-Aguado A, et al. Direct cost of management and treatment of active systemic lupus erythematosus and its outbreaks in Spain: the LUCIE Study. Rev Clin Esp. 2013;213(3):127–137. doi:10.1016/j.rce.2012.11.01823398815
   PubMedGoogle Scholar
• Zink A, Fischer-Betz R, Thiele K, et al. Health care and burden of disease in systemic lupus erythematosus compared to rheumatoid arthritis: results from the National Database of the German Collaborative Arthritis Centers. Lupus. 2004;13(7):529–536. doi:10.1191/0961203304lu1054oa15352425
   PubMedGoogle Scholar
• Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. 2014;17(1):5–14. doi:10.1016/j.jval.2013.08.229124438712
   PubMed Web of Science ®Google Scholar
• INE. Resident population by date, sex and age. National results. Inst Nac Statistics 2017
   Google Scholar
• Spanish Society of Rheumatology. Episer studio. Available from: http://www.ser.es/episer/ Accessed 1025, 2019.
   Google Scholar
• Cevey M, Calvo-Alén J, Crespo C, Robles-Marhuenda A, Cortés J. Systemic lupus erythematosus in Spain in patients with high activity of the disease in the next 5 years. Reumatol Clin. 2018;14(Spec Cong):28–286.
   Google Scholar
• Somers EC, Marder W, Lewis EE, et al. Michigan Lupus Epidemiology & Surveillance Program (MILES): increased proportion of target-organ threatening involvement among male versus female SLE patients In: American College of Rheumatology ACR-ARP Annual Meeting. Philadelphia (PA); 2009:235 [Abstract # 302].
   Google Scholar
• Rúa-Figueroa Í, Richi P, López-Longo FJ, et al. Comprehensive description of clinical characteristics of a large systemic lupus erythematosus cohort from the spanish rheumatology society lupus registry (RELESSER) with emphasis on complete versus incomplete lupus differences. Med (United States). 2015;94(1):e267. doi:10.1097/MD.0000000000000267
   Web of Science ®Google Scholar
• Summary Product of Characteristics of Benlysta (belimumab) subcutaneous. GlaxoSmithKline. 2018 Available from: https://cima.aemps.es/cima/pdfs/en/ft/111700004/FT_111700004.pdf Accessed 1025, 2019.
   Google Scholar
• Ipsos Healthcare. Lupus Monitor market research 2016. Madrid 2017
   Google Scholar
• Study Group of Systemic Autoimmune Diseases (GEAS). Spanish Society of Internal Medicine (SEMI). Clinical Guidelines of Systemic Autoimmune Diseases. Disseminated Lupus Erythematosus. 2011. Available from: https://www.fesemi.org/sites/default/files/documentos/publicaciones/guia_les_2011.pdf. Accessed 11 08, 2019.
   Google Scholar
• National Statistics Institute. Mortality tables by year, sex, age and functions. Results by Autonomous Communities and Provinces. Inst Nac Statistics. 2016 Available from: https://www.ine.es/. Accessed November 27, 2019.
   Google Scholar
• Bultink I, de Vries F, van Vollenhoven R, Lalmohamed A. A population-based study on mortality and the influence of medication use in 4356 patients with systemic lupus erythematosus and 21845 matched controls from the United Kingdom. Lupus Sci Med. 2018;5(Suppl 1):S6A: 4.
   Google Scholar
• Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006;54(8):2550–2557. doi:10.1002/art.2195516868977
   PubMed Web of Science ®Google Scholar
• Rúa-Figueroa I, López-Longo FJ, Calvo-Alén J, et al. National registry of patients with systemic lupus erythematosus of the Spanish Society of Rheumatology: objectives and methodology. Clinical Reumatol. 2014;10(1):17–24. doi:10.1016/j.reuma.2013.04.013
   PubMedGoogle Scholar
• Consejo General de Colegios Oficiales. Database of Medicine. Bot Plus. 2017
   Google Scholar
• Summary Product of Characteristics of Benlysta (belimumab) for solution for infusion. GlaxoSmithKline. 2018 Available from: https://cima.aemps.es/cima/dochtml/ft/11700001/FT_11700001.html Accessed 1025, 2019.
   Google Scholar
• Stohl W, Schwarting A, Okada M, et al. Efficacy and safety of subcutaneous belimumab in systemic Lupus Erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study. Arthritis Rheum (Hoboken, NJ). 2017;69(5):1016–1027. doi:10.1002/art.40049
   PubMed Web of Science ®Google Scholar
• AEMPS. Technical Sheet Subcutaneous Benlysta. Madrid; 2018 Available from: https://cima.aemps.es/cima/pdfs/en/ft/111700004/FT_111700004.pdf Accessed 1025, 2019.
   Google Scholar
• National Institute of Statistics European Survey of Health in Spain National results. Madrid 2017
   Google Scholar
• Official Gazette of Aragon ORDER of September 17, 2015, of the Directors of the Treasury and Public Administration and of Health, by which the Public Prices for the Provision of Services or Realization of Own Activities of the Aragonese Public Bank Entity are Created. Saragossa; 2015
   Google Scholar
• Official Gazette of Cantabria Approval of the Price Tariff of the Products and Services Provided by the Blood and Tissue Bank of Cantabria for the Year 2017 in the Autonomous Region of Cantabria. Santander; 2017
   Google Scholar
• Banc de sang i teixits de Catalunya. Llista de Preus. Barcelona; 2018
   Google Scholar
• Official Bulletin of the Canary Islands. Resolution of March 29, 2017, of the Director, by which the Amount of the Public Prices of Sanitary Services Provided is Modified in Decree 81/2009, of June 16, Whereby the Public Prices of Health Services are Established P. 2017
   Google Scholar
• Official Gazette of Aragon RESOLUTION of July 30, 2012, of the Management of the Aragonese Health Service, on Revision of the Fees to be Applied for the Provision of Sanitary Services to Third Parties Obligatory to the Payment or to Users Without Right to Sanitary Assistance in L. Zaragoza; 2012.
   Google Scholar
• Official Gazette of the Region of Murcia Ministry of Finance and Public Administration. Order of February 16, 2017 Number 48. Murcia; 2017
   Google Scholar
• OSAKIDETZA (Basque Health Service) Rates for Invoicing of Sanitary Services and Teachers of Osakidetza for the Year 2018. Vitoria; 2018
   Google Scholar
• Official Gazette of La Rioja Resolution Number 169, of January 26, 2012, of the Minister of Health and Social Services for which the Publication of the Rates for Health Services Provided to Individuals is Provided in the Centers of the Riojan Health Service. Logroño; 2012.
   Google Scholar
• Official Diari of the Generalitat de Catalunya. SLT/30/2013, of February 20, Whereby the Public Prices of the Catalan Health Service are Approved. Barcelona 2013.
   Google Scholar
• Official Bulletin of Madrid. ORDER 727/2017, of August 7, of the Minister of Health, by which the Public Prices for the Provision of the Services and Activities of Sanitary Nature of the Network of Centers of the Community of Madrid are Fixed. Madrid 2017
   Google Scholar
• Official Gazette of the Council of Andalusia ORDER of October 14, 2005, Whereby the Public Prices of Health Services Provided by Dependent Centers of the Public Health System of Andalusia. Sevilla, 2005.
   Google Scholar
• Parks D, Ramachandran S, Kurtinecz M, Asukai Y, Alfonso-Cristancho R. Indirect comparative clinical effectiveness of intravenous and subcutaneous formulations of Benlysta for the treatment of adult patients with active, autoantibody-positive systemic lupus erythematosus with high disease activity. Ann Rheum Dis. 2017;76(Suppl 2).
   Google Scholar
• Cevey M, Calvo-Alén J, Crespo C, Robles-Marhuenda A, Cortés J Direct cost offsets related to belimumab subcutaneous administration in patients with systemic lupus erythematosus in Spain. Available from: https://tools.ispor.org/ScientificPresentationsDatabase/Presentation/85326?pdfid=56520 Accessed 1025, 2019.
   Google Scholar
• Ministry of Health, Social Services and Equality Institute of Health Information. Registration of registrations – CMBD 2015. MSSSI 2017. Available from: https://www.msssi.gob.es/estadEstudios/estadisticas/sisInfSanSNS/aplicacionesConsulta/home.htm Accessed 11 2017
   Google Scholar
• Boletín Oficial de Canarias. Resolución de 29 de Marzo de 2017, Del Director, Por La Que Se Modifica La Cuantía de Los Precios Públicos de Servicios Sanitarios Previstos En El Decreto 81/2009, de 16 de Junio, Por El Que Se Establecen Los Precios Públicos de Los Servicios Sanitarios P.; 2017.
   Google Scholar
• Boletín oficial de Aragón. Resolución de 30 de Julio de 2012, de La Dirección Gerencia Del Servicio Aragonés de Salud, Sobre Revisión de Las Tarifas a Aplicar Por La Prestación de Servicios Sanitarios a Terceros Obligados Al Pago o a Usuarios Sin Derecho a Asistencia Sanitaria En L. Zaragoza; 2012.
   Google Scholar
• Osakidetza. Tarifas Para Facturación de Servicios Sanitarios y Docentes de Osakidetza Para El Año 2018. Vitoria; 2018.
   Google Scholar
• Boletín oficial de La Rioja. Resolución Número 169, de 26 de Enero de 2012, Del Consejero de Salud y Servicios Sociales Por La Que Se Dispone La Publicación de Las Tarifas Por Servicios Sanitarios Prestados a Particulares En Los Centros Del Servicio Riojano de Salud. Logroño; 2012.
   Google Scholar
• Diari Oicial de la Generalitat de Catalunya. SLT/30/2013, de 20 de Febrero, Por La Que Se Aprueban Los Precios Públicos Del Servicio Catalán de La Salud. Barcelona; 2013.
   Google Scholar
• Boletín oficial de Madrid. Orden 727/2017, de 7 de Agosto, Del Consejero de Sanidad, Por La Que Se Fijan Los Precios Públicos Por La Prestación de Los Servicios y Actividades de Naturaleza Sanitaria de La Red de Centros de La Comunidad de Madrid. Madrid; 2017.
   Google Scholar
• Boletín Oficial de la Junta de Andalucía. Orden de 14 de Octubre de 2005, Por La Que Se Fijan Los Precios P–blicos de Los Servicios Sanitarios Prestados Por Centros Dependientes Del Sistema Sanitario Público de Andalucía. Sevilla; 2005.
   Google Scholar
• Stohl W, Schwarting A, Okada M, et al. Efficacy and safety of subcutaneous Benlysta in systemic lupus erythematosus: a randomized, double-blind, placebo-controlled, 52-week study. Arthritis Rheum. 2017. doi:10.1002/art.40049
   Web of Science ®Google Scholar
• Cortés J, Andreu JL, Calvo J, et al. Evaluation of use of benlysta in clinical practice settings (Observe Study) in Spain: health resource utilization and labor absenteeism. Value Health. 2014;17(7):A534. doi:10.1016/j.jval.2014.08.1703
   PubMed Web of Science ®Google Scholar
• Parks D, Ramachandran S, Kurtinecz M, Asukai Y, Alfonso-Cristancho R. SAT0223 indirect comparative clinical effectiveness of intravenous and subcutaneous formulations of belimumab for the treatment of adult patients with active, autoantibody-positive systemic lupus erythematosus with high disease activity In: EULAR Congress. Poster Presentations. BMJ Publishing Group Ltd and European League Against Rheumatism; 2017:857.3–858. doi:10.1136/annrheumdis-2017-eular.4701
   Google Scholar
• Strand V, Levy RA, Cervera R, et al. Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomized controlled BLISS trials. Ann Rheum Dis. 2014;73(5):838–844. doi:10.1136/annrheumdis-2012-20286523524886
   PubMed Web of Science ®Google Scholar
• Seoane-Mato D, Sánchez-Piedra C, Silva-Fernández L, et al. Prevalence of rheumatic diseases in the adult population in Spain (EPISER 2016 study). III. Objectives and methodology. Clinical Reumatol. 2017. doi:10.1016/j.reuma.2017.06.009
   Web of Science ®Google Scholar